Abstract
The clinical picture of autoimmune hepatitis (AIH) varies markedly between patients, potentially due to genetic modifiers. The aim of this study was to evaluate genetic variants previously associated with fatty liver as potential modulators of the AIH phenotype. The study cohort comprised 313 non-transplanted adults with AIH. In all patients, the MARC1 (rs2642438), HSD17B13 (rs72613567), PNPLA3 (rs738409), TM6SF2 (rs58542926), and MBOAT7 (rs641738) variants were genotyped using TaqMan assays. Mitochondrial damage markers in serum were analyzed in relation to the MARC1 variant. Carriers of the protective MARC1 allele had lower ALT and AST (both P < 0.05). In patients treated for AIH for ≥ 6 months, MARC1 correlated with reduced AST, ALP, GGT (all P ≤ 0.01), and lower APRI (P = 0.02). Patients carrying the protective MARC1 genotype had higher total antioxidant activity (P < 0.01) and catalase levels (P = 0.02) in serum. The PNPLA3 risk variant was associated with higher MELD (P = 0.02) in treated patients, whereas MBOAT7 increased the odds for liver cancer (OR = 3.71). None of the variants modulated the risk of death or transplantation. In conclusion, the MARC1 polymorphism has protective effects in AIH. Genotyping of MARC1, PNPLA3, and MBOAT7 polymorphisms might help to stratify patients with AIH.
Similar content being viewed by others
Introduction
Autoimmune hepatitis (AIH) is a progressive liver disease, which, if untreated, leads to liver cirrhosis1. Therapy for AIH is based on immunosuppression, which induces remission in the majority of patients; some patients may require lifelong maintenance therapy or treatment with alternative, second-line drugs1. The progression of AIH varies markedly between patients2, and up to 30% of patients have liver cirrhosis at the time of diagnosis.
In the last decade, several inherited determinants of liver injury were identified3. For example, the common PNPLA3 p.I148M, MBOAT7 p.G17E, and TM6SF2 p.E167K variants have been shown to increase the risk of liver steatosis, fibrosis, and cirrhosis in patients with nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and with viral liver diseases3,4,5,6. Recently, two variants, HSD17B13 rs72613567:TA7 and MARC1 p.A165T8,9,10, were shown to decrease the risk of developing NAFLD. The MARC1 p.A165T variant was demonstrated to have protective effects in patients with alcoholic liver disease (ALD)11. Rare liver diseases, such as AIH, have not been thoroughly studied in terms of genetic modifiers of their progression. A genome-wide association study (GWAS) in 649 adults with AIH from the Netherlands identified human leukocyte antigen (HLA) loci, HLA-DRB1*0301 and HLA-DRB1*0401, as susceptibility genotypes12, which was in line with other genetic studies on AIH13,14,15. The strongest non-HLA susceptibility marker was found to be SH2B312, which was also reported to increase the risk of developing other autoimmune diseases, such as primary sclerosing cholangitis (PSC)16, primary biliary cholangitis (PBC)17, and type 1 diabetes mellitus18. Analyses of PBC and PSC risk loci in patients with AIH without cholestatic variants revealed that part of the genetic susceptibility for AIH coincides with PBC and PSC12. Other non-HLA susceptibility polymorphisms, for example, tumor necrosis factor alfa (TNF-alpha)19 or vitamin D receptor (VDR)20,21, were also associated with AIH in the previous studies. A recently published single-center analysis of 239 adult patients with AIH demonstrated that carriers of the minor PNPLA3 p.I148M allele are characterized by advanced liver fibrosis according to the AST to Platelet Ratio Index (APRI) and Fibrosis-4 Index (FIB-4)22. Furthermore, it was shown that the PNPLA3 p.148MM genotype might increase the odds of liver transplantation or death in patients with AIH22; however, these results have not yet been validated in other cohorts of patients with AIH.
In our current study, we investigate the role of inherited predisposition in the progression of liver injury in patients with AIH. To this end, we genotyped PNPLA3, MBOAT7, TM6SF2, HSD17B13, and MARC1 variants in a large cohort of adult patients with AIH and performed the genotype–phenotype analyses.
Patients and methods
Between October 2015 and June 2019, we prospectively enrolled 313 consecutive non-transplanted adults with AIH at the Medical University of Warsaw, Poland. Pure AIH, as well as its cholestatic variants, namely AIH-PSC and AIH-PBC, were diagnosed according to the current guidlines1 (i.e., they were based on liver histology, presence of typical antibodies, elevated serum concentration of immunoglobulin G, and, in cholestatic variants, imaging studies). The diagnosis of AIH-PSC overlap was based on imaging or histological features of PSC combined with features (biochemical, serological, and histological) of AIH. AIH-PBC diagnosis was established according to the “Paris criteria”23. Any acute or chronic liver diseases other than AIH, or its overlap with PSC and PBC, served as exclusion criteria.
The study protocol (KB/128/2015) was approved by the Ethics Committee of the Medical University of Warsaw, according to the ethical guidelines of the 1975 Declaration of Helsinki (latest revision, 2013), and written informed consent was obtained from all participants.
Clinical data
All patients underwent careful clinical examination. Blood samples were drawn from fasted subjects. Non-invasive measurements for liver fibrosis and blood tests were performed in all patients on the same day, i.e., upon enrolment in the study. Liver fibrosis was non-invasively quantified using real-time 2D-SWE by Aixplorer (SuperSonic Imagine, Aix-en-Provence, France), as described previously24, and is presented as LSM. The following serum fibrosis indices were calculated as follows: FIB-4 was calculated according to Sterling et al.25, and the APRI was calculated in line with Wai et al.26. Liver biopsies were available in 48 (80%) of therapy-naïve patients; LB was not performed in 12 (20%) of therapy-naïve patients due to ascites, coagulopathy, or lack of patient consent. Biopsies were analyzed by a pathologist experienced in liver diseases using the Batts and Ludwig27 system for the assessment of liver fibrosis and inflammation. The available clinical data from the follow-up were used to examine changes in blood tests in relation to the studied polymorphisms.
Given the differences between pure AIH and its cholestatic variants, we performed genotype–phenotype association tests in the entire cohort of patients and separately in subsets of patients with pure AIH and with AIH-PSC or AIH-PBC. The subgroup of patients with pure AIH was divided in relation to the immunosuppressive therapy (i.e., therapy ≥ 6 months or therapy-naïve).
Data at diagnosis, clinical outcome, and hepatocellular carcinoma
In addition to the data collected at baseline, we analyzed the association between the studied polymorphisms and (1) age and presence of liver cirrhosis at diagnosis, as well as the type of AIH; (2) clinical outcome defined as a combined endpoint: liver transplantation (LT) or liver-related death; and (3) hepatocellular carcinoma (HCC). Due to the relatively small number of patients who reached the clinical endpoint in the study group (n = 66, 21%), the additional cohort of 30 patients after LT for AIH (57% female, median age at diagnosis 33 (range 8–62) years, median age at LT 35 (range 12–67) years) was included in this analysis. The diagnosis of HCC was established by imaging studies (CT or MRI) and confirmed by histology, if available.
Genotyping
Genotyping of the MARC1 (rs2642438), PNPLA3 (rs738409), TM6SF2 (rs58542926), MBOAT7 (rs641738), and HSD17B13 (rs72613567) gene variants was performed at Saarland University Medical Center in Homburg, Germany, by technicians blinded to the phenotype of patients. A detailed description of genotyping is provided in Supplementary Text S1 and Table S1.
Hepatocyte mitochondrial damage in relation to the MARC1 genotype
How MARC1 may impact liver damage is unclear; however, this signal-anchored mitochondrial protein28 is associated with detoxification reactions29. Thus, we evaluated the presence of oxidative stress-induced mitochondrial damage markers of hepatocytes in serum. The level of mitochondrial uncoupling protein 2 (UCP2) (an inner mitochondrial membrane marker) and two antioxidant enzymes, thioredoxin reductase 2 (TrxRd2) and superoxide dismutase 2 (SOD2) (mitochondrial matrix markers), in the serum of 39 individuals carrying either the wild-type (n = 25) or the homozygous (n = 14) MARC1 variant were evaluated. This cohort was randomly selected from the pure AIH group (without AIH overlap with PSC and PBC) treated for at least 6 months. Patients for this analysis were randomly selected from the AIH cohort using SPSS software (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.).
Western blot analysis
The presence of antioxidant enzymes: ubiquitous catalase (CAT) and mitochondrially located TrxRd2 and SOD2, or mitochondrial proteins like UCP2 in serum, which could be linked to damage of hepatocytes, was evaluated with the use of specific antibodies, as described in detail in Supplementary Text S2.
Determination of oxidative damage markers in serum
Lipid peroxidation (LPO) in serum was evaluated by measuring malondialdehyde (MDA) (a major reactive aldehyde resulting from the peroxidation of biological membranes) using the Lipid Peroxidation Assay Kit from Abcam (ab118970, Cambridge, U.K.). Serum protein oxidative damage was estimated using OxyBlot Protein Oxidation Detection Kit (S7150, Sigma-Aldrich, MO, USA). A detailed description of the performed experiments is provided in Supplementary Text S2.
Serum total antioxidant activity
The concentration of small molecule antioxidants and small protein antioxidants in serum samples was analyzed by measuring the total antioxidant activity (TAA) following the ABTS/H2O2/HRP method developed by Arnao30 with modifications by Gonzalo-Calvo31 (Supplementary Text S2).
Statistical analyses
Statistical analyses were performed using SPSS (IBM Corp. Released 2020. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp.) and GraphPad Prism (GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego, California USA, http://www.graphpad.com). The consistency of genotyping results with the Hardy–Weinberg equilibrium (HWE) was tested by exact tests (https://ihg.gsf.de/cgi-bin/hw/hwa1.pl). A two-sided P-value < 0.05 was considered statistically significant. Kolmogorov–Smirnov or Shapiro–Wilk tests were used to determine whether the set of observations followed normal distributions. Student’s t and Mann–Whitney U tests were used to study normally and non-normally distributed parameters, respectively. Analyses of variance (ANOVA) and Kruskal–Wallis tests were applied to study differences between three groups with normally and non-normally distributed parameters, respectively. The Wilcoxon signed-rank test was used to compare paired blood test results from baseline and follow-up. The associations between gene variants and follow-up data were tested by logistic regression analyses. Principal component analysis (PCA) was performed with R (2020, R Core Team, Vienna, Austria). The impact of the tested polymorphisms on the clinical endpoint (defined as LT or liver-related death), as well as diagnosis of HCC, was estimated with Cox regression and Kaplan–Meier survival analysis.
Results
Description of the study cohort
Clinical details of the study cohort are presented in Table 1. In total, 313 adults with AIH (70% women) were recruited; their median age was 36 (range 18–83) years. Pure AIH, AIH-PSC, and AIH-PBC were diagnosed in 206 (66%), 77 (25%), and 30 (9%) recruited patients, respectively. The median duration of the disease was 4 (range 0–33) years. In total, 60 (19%) patients were therapy naïve at inclusion. Liver cirrhosis, diagnosed by LB or LSM and by clinical signs of decompensation, was present in 130 (42%) patients at the enrolment in the study. Almost 70% of the entire cohort received steroid-based therapy, which is summarized in Table 1. Almost all patients with cholestatic variants were treated with ursodeoxycholic acid. Approximately 40% of patients were on steroid-based therapy after 2 years of therapy, whereas more than 20% of cases achieved long-term biochemical remission (more than 2 years) and were not receiving immunosuppression at the baseline.
MARC1 shows protective effects in patients with AIH
The five genetic variants were successfully genotyped in all patients. Table 2 presents the distributions of genotypes. All variants were within the Hardy–Weinberg equilibrium, underscoring robust genotyping.
The MARC1 polymorphism showed prominent modulating effects on the AIH phenotype. In the entire cohort of 313 individuals, carriers of the MARC1 minor allele had significantly lower serum activities of ALT (P = 0.04) and AST (P = 0.02) (Fig. 1A,B) at baseline. Comparable results were found in patients with pure AIH (n = 206); carriers of at least one minor allele had significantly lower serum ALT (P = 0.03) and AST activities (P = 0.02) (Fig. 1C,D).
Figure 2 shows the results of 146 patients with pure AIH who were treated for ≥ 6 months. In these patients, the frequency of individuals with normal ALT increased with the number of protective MARC1 alleles (Fig. 2A). As shown in Fig. 2B, carriers of the protective MARC1 allele had significantly lower serum AST activities (P = 0.01), and homozygous carriers of the protective allele presented with lower ALP (P < 0.01, Fig. 2C) and GGT activities (P < 0.01, Fig. 2D) as compared to patients with the wild-type genotype. Carriers of the MARC1 minor allele also had lower APRI (median 0.61, range 0.15–7.28) compared to the carriers of the wild-type genotype (median 0.81, range 0.18–14.04; P = 0.02). Finally, the MARC1 p.A165T polymorphism was associated with lower immunoglobulin G (IgG) concentrations (P < 0.01) among AIH patients with elevated IgG levels (> 1600 mg/dL; n = 53). LSM, MELD, and liver histology were not modulated by this polymorphism.
Among patients who were followed up for 12 months (data available for 145 patients), carriers of at least one MARC1 p.A165T allele showed lower ALT and AST activities at baseline (both P < 0.05) compared to carriers of the wild-type genotype (Supplementary Table S2). Moreover, the presence of at least one MARC1 allele was also associated with a trend (P = 0.05) for improved FIB-4 during follow-up (Supplementary Table S2).
The results of the genotype–phenotype association analysis in a subgroup of patients with AIH-PSC and AIH-PBC are presented in Supplementary Text S3 and Fig. S1.
PNPLA3 variant is associated with a higher MELD score, whereas the MBOAT7 polymorphism might modulate HCC risk
A significantly higher MELD score (P = 0.02, Fig. 3) among patients with pure AIH treated ≥ 6 months (n = 146) who carried at least one PNPLA3 p.148M risk allele was the only association between patients’ characteristics and the PNPLA3 variant at baseline. Regardless of increasing MELD, the presence of this allele did not increase the risk of transplantation or death (1.03, 95% CI 0.73–1.46, P = 0.86) and did not affect survival in Kaplan–Meier analysis. During the 12-month follow-up, patients with the PNPLA3 wild-type genotype showed a significant (P = 0.03) decrease in serum ALT activity, whereas a trend to increased FIB-4 during the follow-up period was observed in carriers of at least one PNPLA3 p.148M risk allele (P = 0.06, Supplementary Table S3).
HSD17B13, TM6SF2, and MBOAT7 variants were not associated with liver function tests, LSM, FIB-4, APRI, or MELD (all P > 0.05). Moreover, none of the tested polymorphisms was associated with prolonged steroid-based treatment (i.e., ≥ 2 years) or cirrhosis at diagnosis. None of the five studied genetic variants was associated with LT or death (all P > 0.05) in our cohort.
HCC was diagnosed in eight patients, all with cirrhosis. Interestingly, we found an association between MBOAT7 and HCC. All but one patient diagnosed with HCC carried at least one MBOAT7 minor allele [T]. Accordingly, the MBOAT7 [TT] genotype was associated with an increased risk of developing HCC (odds ratio (OR) 3.71, 95% CI 1.22–11.28, P = 0.02). No other evaluated polymorphisms were found to modify the risk of HCC in our study.
Presence of the protective MARC1 variant is associated with increased antioxidant capacity
Based on the above results that linked the MARC1 polymorphism to liver injury biomarkers, we performed further evaluation. We randomly selected 25 individuals carrying the MARC1 wild-type genotype [GG] and 14 MARC1 homozygous carriers of the protective allele [AA]. Supplementary Table S4 summarizes the characteristics of these patients. Both groups of patients did not differ significantly in terms of clinical characteristics, apart from lower ALP among carriers of the protective variant. As reflected by PCA (Supplementary Fig. S2), the stages of liver disease (i.e., FIB-4, LSM, and MELD) did not differ between carriers of the MARC1 genotypes. The TAA in serum, which represents small-molecule and protein antioxidants, was higher in patients carrying the MARC1 variant compared to the wild-type genotype (P = 0.003, Fig. 4A). Moreover, the catalase levels in carriers of the MARC1 protective allele were also increased (P = 0.02, Fig. 4B; Supplementary Fig. S3). On the other hand, the levels of SOD2 and TrxRd2, two antioxidant enzymes involved in the mitochondrial antioxidant defense system, did not differ (Fig. 4C,D; Supplementary Fig. S3). Interestingly, the higher antioxidant capacity (TAA) and higher levels of catalase observed in MARC1 homozygotes correlated with an increase in oxidatively damaged lipids (peroxidation), while the level of carbonylated proteins remained unchanged (Fig. 4E,F; Supplementary Fig. S4). The level of UCP2 was similar in serum samples from carriers of the MARC1 variant and patients carrying the MARC1 wild-type genotype (P > 0.05, Fig. 4G; Supplementary Fig. S3). This finding is supported by above-described observation that the levels of other mitochondrial proteins (SOD2 and TrxRd2), associated with the antioxidant response and localized in the mitochondrial matrix, did not change either similarly to UCP2 (Fig. 4C,D; Supplementary Fig. S3).
Discussion
In this study, we aimed to investigate the role of genetic predisposition as a modulator of AIH. By analyzing an extensive cohort of patients, we detected lower indices of liver injury in the carriers of the MARC1 p.A165T polymorphism. This observation was coupled with the improved marker of liver fibrosis, APRI, in patients treated for AIH for at least 6 months. Analyses of patients blood samples demonstrated that the effects of the MARC1 polymorphism might be related to increased antioxidant capacity in the sera of patients carrying the protective genotype. Moreover, we observed that PNPLA3 p.I148M was associated with higher MELD and that the MBOAT7 polymorphism was linked to an increased risk of developing HCC in the course of AIH.
The presence of the inherited modifiers of AIH was previously suspected32. Since AIH encompasses a heterogeneous group of patients, we decided to analyze both the entire cohort and as well as separate subgroups of patients based on the duration of therapy and the presence of cholestatic variants of AIH. By analyzing the entire group of 313 patients, we detected lower serum transaminase activities among patients carrying the MARC1 polymorphism. This association was also apparent in individuals that were treated for AIH for at least 6 months: they have lower transaminases and lower APRI score. The effect of the MARC1 polymorphism on liver fibrosis marker was maintained during the 12-month follow-up. On the other hand, we did not detect any significant effect of MARC1 on the results of liver biopsies. It has to be kept in mind that not all patients in our cohort received liver biopsies at baseline. Patients with already established diagnoses (confirmed by previously performed liver biopsy before referral to our center) and during maintenance therapy did not undergo liver biopsy at inclusion. This relatively low number of liver biopsies lowered the power of this analysis. Overall, we believe that although the presence of the MARC1 minor allele is associated with decreased serum markers of liver injury, this polymorphism has only limited effects on the progression of liver fibrosis. This is also underscored by the lack of association between this variant and LSM.
MARC1 is an enzyme attached to the mitochondrial membrane, a molybdenum-containing nitric oxide synthase that reduces the physiological substrate N(omega)-hydroxy-l-arginine. Luukkonnen et al. showed that the minor allele might increase intrahepatic phosphatidylcholines9. The missense variant p.A165T in MARC1 was previously linked to protection against cirrhosis, lower hepatic fat contents, and lower risk of developing fatty liver8. In our cohort, the MARC1 protective variant correlated with increased antioxidant capacity, manifested as an increased level of catalase (ubiquitous primary antioxidant enzyme) and increased total antioxidant activity in serum. The increased antioxidant capacity can also be considered as a response to counteract augmented oxidative stress, which is mirrored by higher lipid peroxidation in MARC1 homozygotes. Interestingly, the MARC1 genotype seemed to be the main driver of changes in antioxidant capacity since other clinical characteristics, apart from lower ALP, did not differ between patients included in this analysis (Supplementary Table 4). The unchanged level of mitochondrial markers, reported in the literature to be present in the serum of the patients with severe liver damage33,34, supports the assumption that increased antioxidant capacity can play a protective role in patients carrying the protective MARC1 polymorphism.
The genetic variants that we chose to genotype in our patients with AIH were previously shown to modify liver fibrosis and/or steatosis in patients with viral, alcoholic, and non-alcoholic fatty liver disease3,35,36. To date, studies concerning the role of genetics on AIH have mainly focused on the associations with human leukocyte antigen13,14,15. In a recent analysis, the common PNPLA3 p.I148M polymorphism was associated with the progression of AIH22 and clinical endpoints, defined as LT or death22. In our study, we were not able to replicate any of these findings; however, we found an association between the PNPLA3 variant and higher MELD. Survival analyses of our patients disclosed no correlation between liver transplantation or death and the studied variants (of note, 96 (28%) patients reached these endpoints). The differences between the findings of our study and those of a previous publication22 underscore the heterogeneity of patients with AIH and the different diagnostic and therapeutic strategies established in each center. Our center serves as a referral unit for patients with AIH in Poland, which might be one of the reasons why our cohort was characterized by a high prevalence of AIH-PSC and AIH-PBC overlaps with a relatively high number of patients with cirrhosis. These variants of AIH are typically more difficult to treat, with a wide variation in clinical decisions together with these patients, even in referral centers37.
We detected a potential link between the MBOAT7 polymorphism and the risk of developing HCC. In our study group, eight patients had HCC, which is in line with other reports that indicated a relatively low prevalence of HCC in AIH1. MBOAT7 was previously identified as a risk factor of HCC38, and we report for the first time this association in patients with AIH. However, given the low incidence of this tumor in autoimmune liver diseases, replication in a larger cohort is necessary to confirm this result.
In conclusion, in our candidate gene study, we found potential protective effects of the MARC1 polymorphism in patients with AIH. The PNPLA3 and MBOAT7 variants might be associated with a more severe AIH. These results allude to the role of inherited predisposition in the course of AIH. Analyses of intracellular processes that are affected by the studied variants might provide new functional insights into the pathogenesis of AIH.
Abbreviations
- AIH:
-
Autoimmune hepatitis
- ALP:
-
Alkaline phosphatase
- ALT:
-
Alanine aminotransferase
- APRI:
-
Aspartate aminotransferase to platelet ratio index
- AST:
-
Aspartate aminotransferase
- CAT:
-
Catalase
- FIB-4:
-
Fibrosis-4
- GWAS:
-
Genome-wide association study
- HLA:
-
Human leukocyte antigen
- HCC:
-
Hepatocellular carcinoma
- HSD17B13:
-
Hydroxysteroid 17β-dehydrogenase 13
- IgG:
-
Immunoglobulin G
- LB:
-
Liver biopsy
- LSM:
-
Liver stiffness measurement
- LT:
-
Liver transplantation
- UNL:
-
Upper normal limit
- MARC1:
-
Mitochondrial amidoxime-reducing component 1
- MBOAT7:
-
Membrane-bound O-acyltransferase domain containing 7
- MELD:
-
Model of end-stage liver disease
- NAFLD:
-
Non-alcoholic fatty liver disease
- PBC:
-
Primary biliary cholangitis
- PLT:
-
Platelet count
- PNPLA3:
-
Patatin-like phospholipase domain-containing protein 3
- PSC:
-
Primary sclerosing cholangitis
- SOD2:
-
Superoxide dismutase 2
- TAA:
-
Total antioxidant activity
- TM6SF2:
-
Transmembrane 6 superfamily member 2
- TrxRd2:
-
Thioredoxin reductase 2
- UCP2:
-
Uncoupling protein 2
References
Lohse, A. W. et al. EASL clinical practice guidelines: Autoimmune hepatitis. J Hepatol. 63(4), 971–1004. https://doi.org/10.1016/j.jhep.2015.06.030 (2015).
Dhaliwal, H. K. et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am. J. Gastroenterol. 110(7), 993–999. https://doi.org/10.1038/ajg.2015.139 (2015).
Krawczyk, M., Liebe, R. & Lammert, F. Toward genetic prediction of nonalcoholic fatty liver disease trajectories: PNPLA3 and beyond. Gastroenterology 158(7), 1865-1880.e1. https://doi.org/10.1053/j.gastro.2020.01.053 (2020).
Krawczyk, M., Grünhage, F., Zimmer, V. & Lammert, F. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: Non-invasive elastography-based study in chronic liver disease. J. Hepatol. 55(2), 299–306. https://doi.org/10.1016/j.jhep.2010.10.042 (2011).
Falleti, E. et al. PNPLA3 rs738409C/G polymorphism in cirrhosis: Relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence. Liver Int. 31(8), 1137–1143. https://doi.org/10.1111/j.1478-3231.2011.02534.x (2011).
Trépo, E. et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J. Hepatol. 55(4), 906–912. https://doi.org/10.1016/j.jhep.2011.01.028 (2011).
Abul-Husn, N. S. et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N. Engl. J. Med. 378(12), 1096–1106. https://doi.org/10.1056/NEJMoa1712191 (2018).
Emdin, C. A., Haas, M. E., Khera, A. V. et al. A missense variant in mitochondrial amidoxime reducing component 1 gene and protection against liver disease. PLoS Genet. 16(4) (2020). https://doi.org/10.1371/journal.pgen.1008629
Luukkonen, P. K. et al. MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans. J. Hepatol. 73(3), 725–726. https://doi.org/10.1016/j.jhep.2020.04.021 (2020).
Hudert, C., Alisi, A., Anstee, Q. et al. Variants in MARC1 and HSD17B13 reduce severity of NAFLD in children, perturb phospholipid metabolism, and suppress fibrotic pathways. medRxiv. https://doi.org/10.1101/2020.06.05.20120956
Innes, H. et al. Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1. Gastroenterology 159(4), 1276-1289.e7. https://doi.org/10.1053/j.gastro.2020.06.014 (2020).
De Boer, Y. S., Van Gerven, N. M. F., Zwiers, A. et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 147(2) (2014). https://doi.org/10.1053/j.gastro.2014.04.022
Donaldson, P. T. et al. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 13(4), 701–706. https://doi.org/10.1002/hep.1840130415 (1991).
Czaja, A. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 25(2), 317–323. https://doi.org/10.1053/jhep.1997.v25.pm0009021941 (1997).
Milkiewicz, P., Hubscher, S. G., Skiba, G., Hathaway, M. & Elias, E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation 68(2), 253–256. https://doi.org/10.1097/00007890-199907270-00016 (1999).
Liu, J. Z. et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat. Genet. 45(6), 670–675. https://doi.org/10.1038/ng.2616 (2013).
Liu, J. Z. et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 44(10), 1137–1141. https://doi.org/10.1038/ng.2395 (2012).
Barrett, J. C. et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 41(6), 703–707. https://doi.org/10.1038/ng.381 (2009).
Czaja, A. J. et al. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology https://doi.org/10.1016/S0016-5085(99)70458-0 (1999).
Vogel, A., Strassburg, C. P. & Manns, M. P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology https://doi.org/10.1053/jhep.2002.30084 (2002).
Kempinska-Podhorodecka, A. et al. Vitamin-D receptor-gene polymorphisms affect quality of life in patients with autoimmune liver diseases. Nutrients 12(8), 1–13. https://doi.org/10.3390/nu12082244 (2020).
Mederacke, Y. S. et al. The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. Aliment Pharmacol. Ther. 51(11), 1160–1168. https://doi.org/10.1111/apt.15722 (2020).
Chazouillères, O. et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 28(2), 296–301. https://doi.org/10.1002/hep.510280203 (1998).
Janik, M. K. et al. Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis. Liver Int. 41(2), 348–356. https://doi.org/10.1111/liv.14726 (2021).
Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43(6), 1317–1325. https://doi.org/10.1002/hep.21178 (2006).
Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38(2), 518–526. https://doi.org/10.1053/jhep.2003.50346 (2003).
Goodman, Z. D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J. Hepatol. 47(4), 598–607. https://doi.org/10.1016/j.jhep.2007.07.006 (2007).
Klein, J. M. et al. The mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane. J. Biol. Chem. 287(51), 42795–42803. https://doi.org/10.1074/jbc.M112.419424 (2012).
Kubitza, C. et al. Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes. Proc. Natl. Acad. Sci. U.S.A. 115(47), 11958–11963. https://doi.org/10.1073/pnas.1808576115 (2018).
Arnao, M. B., Cano, A. & Acosta, M. The hydrophilic and lipophilic contribution to total antioxidant activity. Food Chem. 73(2), 239–244. https://doi.org/10.1016/S0308-8146(00)00324-1 (2001).
de Gonzalo-Calvo, D. et al. Differential inflammatory responses in aging and disease: TNF-α and IL-6 as possible biomarkers. Free Radic. Biol. Med. 49(5), 733–737. https://doi.org/10.1016/j.freeradbiomed.2010.05.019 (2010).
Krawczyk, M., Müllenbach, R., Weber, S. N., Zimmer, V. & Lammert, F. Genome-wide association studies and genetic risk assessment of liver diseases. Nat. Rev. Gastroenterol. Hepatol. 7(12), 669–681. https://doi.org/10.1038/nrgastro.2010.170 (2010).
Kakisaka, K. et al. Serum markers for mitochondrial dysfunction and cell death are possible predictive indicators for drug-induced liver injury by direct acting antivirals. Hepatol. Res. 48(1), 78–86. https://doi.org/10.1111/hepr.12893 (2018).
Świderska, M., Maciejczyk, M., Zalewska, A., Pogorzelska, J., Flisiak, R. & Chabowski, A. Oxidative stress biomarkers in the serum and plasma of patients with non-alcoholic fatty liver disease (NAFLD). Can plasma AGE be a marker of NAFLD? Oxidative stress biomarkers in NAFLD patients. Free Radic. Res. 53(8), 841–850 (2019). https://doi.org/10.1080/10715762.2019.1635691
Trépo, E. & Valenti, L. Update on NAFLD genetics: From new variants to the clinic. J. Hepatol. 72(6), 1196–1209. https://doi.org/10.1016/j.jhep.2020.02.020 (2020).
Eslam, M., Valenti, L. & Romeo, S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J. Hepatol. https://doi.org/10.1016/j.jhep.2017.09.003 (2018).
Milkiewicz, P. et al. Primary sclerosing cholangitis with features of autoimmune hepatitis: Exploring the global variation in management. Hepatol. Commun. 4(3), 399–408. https://doi.org/10.1002/hep4.1467 (2020).
Donati, B. et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Sci. Rep. 7(1), 4492. https://doi.org/10.1038/s41598-017-04991-0 (2017).
Funding
Open Access funding enabled and organized by Projekt DEAL. M.L-A., Y.P., I.C.M.S. and M.R.W. were supported by the National Science Centre, Poland (UMO-2018/29/B/NZ1/00589). I.C.M.S. was supported by the National Science Centre, Poland (UMO-2020/36/T/NZ1/00004). Moreover, I.C.M.S. and M.R.W. gratefully acknowledge the financial support for this research from the FOIE GRAS and mtFOIE GRAS projects. These projects received funding from the European Union’s Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie Grant Agreement No. 722619 (FOIE GRAS) and Grant Agreement No. 734719 (mtFOIE GRAS). MK was supported by the German Liver Foundation.
Author information
Authors and Affiliations
Contributions
Guarantor of the article: M.K. Specific author contributions: P.M. and M.K. designed and supervised the study; M.K.J., B.K. and P.M. recruited patients and collected the data; W.S., S.W., F. L. and M.K. chose genetic variants and performed/supervised genotyping, B.S. and B.G. analyzed liver biopsies; M.L.-A., Y.P., I.C.M.S. and M.R.W. analysed status of oxidative stress including the level of antioxidant enzymes as well as performed mitochondrial damage markers analyses; M.K.J., W.S., M.R.W. and M.K. analyzed the data, performed the statistical analysis and wrote the first version of the manuscript; all authors made a critical review and edited the manuscript. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Janik, M.K., Smyk, W., Kruk, B. et al. MARC1 p.A165T variant is associated with decreased markers of liver injury and enhanced antioxidant capacity in autoimmune hepatitis. Sci Rep 11, 24407 (2021). https://doi.org/10.1038/s41598-021-03521-3
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-021-03521-3
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.